To hear about similar clinical trials, please enter your email below
Trial Title:
Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion
NCT ID:
NCT05693727
Condition:
Pleural Effusion, Malignant
Conditions: Official terms:
Pleural Effusion, Malignant
Pleural Effusion
Necrosis
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
pleural markers
Description:
Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis
Factor,and Interleukins{2,12,18}
Summary:
To evaluate the ability of cancer ratio and pleural fluid markers to discriminate between
malignant and non malignant effusion
Detailed description:
Pleural effusion is a common clinical entity affecting approximately 1.5 million patients
per year in the United States. {3.1}A large number of diseases may be associated with
pleural effusion.
This includes:
- Local conditions affecting the pleura (eg, tuberculous pleurisy, pleural
mesothelioma),
- Extrapulmonary diseases with secondary pleural involvement (eg, chronic heart
failure, liver cirrhosis).
To date, differentiation between both types of pleural effusion (exudate and transudate)
is the most common initial diagnostic approach for patients with pleural effusion.
Exudative effusion is commonly seen in three conditions namely cancer (MPE), tuberculosis
(TB) and para pneumonic Although MPE can be diagnosed by simple pleural fluid cytology,
this method has significant limitations, including a highly variable sensitivity, ranging
from as low as 11.6% to as high as 71%.
In contrast to other common causes of pleural effusion such as T.B, no accurate
biomarkers of MPE have been established.
Several tumor markers were extensively evaluated, including carcinoembryonic antigen,
cytokeratin-19 fragments, and cancer antigen 125, but none of them were found sensitive
and specific enough to be implemented in routine clinical practice
Criteria for eligibility:
Study pop:
patients with exudative pleural effusion who will be admitted to Department of Chest
diseases and Tuberculosis, Assiut University Hospital
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patients (100 cases) with exudative pleural effusion who will be admitted to
Department of Chest diseases and Tuberculosis, Assiut University Hospital
Exclusion Criteria:
- Age ˂ 18 years
- Refusal to participate in the study
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
September 1, 2023
Completion date:
September 1, 2027
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05693727
https://pubmed.ncbi.nlm.nih.gov/25077579/
https://pubmed.ncbi.nlm.nih.gov/30913213/
